doi: 10.1038/nrneph.2015.131 97 LubkowiczD.HavaD
Safety considerations also warrant attention
Materials and methods GLP-1 peptides GLP-1 peptides, semaglutide (HY-114118, MedChemExpress, Monmouth Junction, NJ, USA), tirzepatide (39748, Cayman Chemical, Ann Arbor, Michigan, USA), and retatrutide (HY-P3506, MedChemExpress) were dissolved in saline (Otsuka Pharma, Tokushima, Japan)
Key Takeaways No Clinical Data Exists (as of 2026): There are currently no published clinical studies or peer-reviewed research specifically examining the safety or efficacy of combining MOTS-c with Retatrutide in human subjects
That might be weight regain, appetite, food noise, blood sugar concerns, emotional eating, low energy, pain, shame, or the feeling that every attempt eventually collapses
Their use in non-diabetics has risen by a staggering 700% in the US between 2019 and 2023.2 Despite its popularity, barriers exist high costs, limited supply, and lack of a structured multidisciplinary obesity programs make their use challenging for many patients